DHH-B, Oral Application
Uses:
- Anxiety
- Mood Stability
- Improves Sleep
Description
DHH-B, dihydrohonokiol-B, is a natural supplement which has anxiolytic-effects. Treatment with DHH-B does not cause any significant changes in motor activity or muscle relaxation. Benzodiazepines are some of the most commonly prescribed medications in the United States. These anxiolytics have many well-known side effects including motor function and more. That being said, this product has the potential to help people transition from benzodiazepines to DHH-B or act as an alternative tobenzodiazepines.
Peptide therapy has emerged as a revolutionary field in the realm of health and well-being. Among its notable advancements, DHH-B stands out as an exceptional peptide with immense potential to improve various aspects of our lives. With its oral application, DHH-B offers a convenient and accessible way to obtain profound benefits for anxiety management, emotional stability, and sleep enhancement. Let’s delve into the world of DHH-B and explore its transformative capabilities.
Anxiety Relief: In an increasingly demanding and fast-paced world, anxiety has become a prevalent concern affecting countless individuals. DHH-B, when administered orally, provides a promising solution for anxiety relief. By targeting key receptors in the brain associated with stress response, this peptide helps regulate anxiety levels and promotes a sense of calm and tranquility. DHH-B’s unique mechanism of action aids in restoring emotional balance, enabling individuals to navigate life’s challenges with enhanced resilience and peace of mind.
Emotional Stability: Maintaining a stable and positive emotional state is essential for overall well-being. DHH-B, when taken orally, plays a significant role in promoting emotional stability. By modulating neurotransmitters and neuropeptides responsible for emotional regulation, this peptide therapy helps restore balance and harmony within the brain. The result is an improved mood state, allowing individuals to experience greater emotional resilience, increased motivation, and an enhanced capacity to cope with everyday stressors.
Improved Sleep Quality: A restful night’s sleep is vital for optimal cognitive function, physical rejuvenation, and overall health. Unfortunately, many individuals struggle with sleep disturbances and insomnia, compromising their well-being. DHH-B offers a ray of hope by targeting sleep-regulating mechanisms in the brain. Through its oral application, this peptide therapy helps promote the release of melatonin, a hormone crucial for sleep regulation. By optimizing sleep patterns and enhancing sleep quality, DHH-B contributes to increased daytime energy, improved focus, and an overall sense of vitality.
DHH-B, through its oral application, represents a remarkable breakthrough in the field of peptide therapy. By addressing anxiety, promoting emotional stability, and improving sleep quality, this peptide therapy empowers individuals to regain control over their mental and emotional health. Embrace the transformative power of DHH-B and embark on a journey towards a harmonious mind, emotional resilience, and restorative sleep. With DHH-B, a brighter and more fulfilling life awaits.
Clinical Research
Comparative assessment of the anxiolytic-like activities of honokiol and derivatives.
A Department of Neuropsychopharmacology (Tsumura), Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan Research Laboratories, Tsumura and Co., Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan Department of Biochemistry, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Honokiol has previously been shown to be an effective anxiolytic-like agent in mice when administered for 7 days at 0.2 mg/kg/day prior to evaluation in an elevated plus-maze, while 20 mg/kg is required for efficacy as a single oral dose. The aim of this study was to find analogs of honokiol that are more effective for acute administration. Among the eight analogs evaluated, one partially reduced derivative of honokiol [30-(2-propenyl)-5- propyl-(1,10-biphenyl)-2,40-diol] exhibited significant anxiolytic-like activity at 0.04 mg/kg. Following oral administration of 1 mg/kg of this analog, anxiolytic-like activity was clearly evident at 1 h, peaked at 3 h, and remained significant for longer than 4 h after treatment. Combined administration of the derivative with diazepam led to enhanced anxiolytic-like efficacy. Moreover, as with diazepam, the anxiolytic-like effect of the analog was reduced by flumazenil. In contrast, bicuculline, a GABAA antagonist, had no effect on the activity of the derivative. Taken together, these results suggest that this analog of honokiol acts at the benzodiazepine recognition site of the GABAA ± benzodiazepine receptor complex.
If you want further information about what DHH-B is or about Peptide Therapy, a member of our Functional Medicine team can help you out by providing you with information about it. Just fill out the form below.
Our highly trained team of professionals at Physiologic NYC is dedicated to providing you with the highest quality of care.
Contact Us